Prof. Paolo Prospero Ghia

Prof. Paolo Prospero Ghia

Medico Interno

Medicina interna, Oncologia

prenota in telemedicina

Lavora presso

IRCCS Ospedale San Raffaele

Lingue parlate

Inglese; Italiano

Formazione

  • Università degli Studi di Torino, Polo di Orbassano
    Specialità in Medicina Interna - 2003
  • Università degli Studi di Torino
    Dottorato di Ricerca in Oncologia Umana - 1996
  • Università degli Studi di Torino
    Laurea in Medicina e Chirurgia - 1990

Pubblicazioni

Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.

Wu SJ, Lin CT, Agathangelidis A, Lin LI, Kuo YY, Tien HF, Ghia P.

Haematologica. 2017 Jun;102(6):1085-1090. doi: 10.3324/haematol.2016.157552. PMID: 28255015

 Visualizza

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.

Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P*, Degano M. *Corresponding author and co-senior author.

Nat Commun. 2017 Jun 9;8:15746. doi: 10.1038/ncomms15746. 

 Visualizza

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.

Agathangelidis A, Ljungström V, Scarfò L, Fazi C, Gounari M, Pandzic T, Sutton LA, Stamatopoulos K, Tonon G, Rosenquist R, Ghia P.

 Haematologica. 2018 Feb 15. pii: haematol.2017.177212. doi: 10.3324/haematol.2017.177212.

 Visualizza

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P.

Haematologica. 2018 Apr 19. pii: haematol.2018.189837. doi: 10.3324/haematol.2018.189837. [Epub ahead of print]PMID: 29674504
 

 Visualizza

Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.

Ghia P, Rawstron A.

Leukemia. 2018 Jun;32(6):1307-1316. doi: 10.1038/s41375-018-0109-x. Epub 2018 Mar 26. PMID: 29700386.

 Visualizza

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P.

Haematologica. 2018 Jun 7. pii: haematol.2018.192328. doi: 10.3324/haematol.2018.192328. PMID: 29880603.
 

 Visualizza

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, Robles A, Gorrochategui J, Martínez-López J, de la Serna J, González M, Gil AC, Anguita E, Iraheta S, Munugalavadla V, Quéva C, Tannheimer S, Rosenquist R, Stamatopoulos K, Ballesteros J, Ghia P.

Oncotarget. 2018 May 25;9(40):26019-26031. doi: 10.18632/oncotarget.25419. eCollection 2018 May 25. PMID: 29899839.
 

 Visualizza

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.

Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E.

Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008. PMID: 29997221. 

 Visualizza

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.

Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259. PMID: 30129285.  

 Visualizza

Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.

Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P.

Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0335-2. PMID: 30607020 

 Visualizza